Cart - $0.00

You have no items in your shopping cart.

Search by:   Algae  •   Bacteria  •  Tree of Life  •  Location (Map)
Quick Order

Quick Order

Exact SKU # Required
Ex. ccmp100-sc
Qty    
  x Remove
  x Remove
  x Remove
  x Remove
  x Remove
+ Add Item

Having trouble find what you are looking for?
Try using the Algae Advanced Search or the Bacteria Search.

Commercialization

The National Center for Marine Algae and Microbiota (NCMA) is an invaluable resource for the algae community around the globe.   As a leading distributor of marine microalgae for science and industry, the NCMA has sold its cultures to more than 2,800 customers in 58 countries.  But we have developed into much more than a biological repository.  We are continually expanding our service capabilities and are currently working with biotech companies worldwide on a wide range of projects.  The projects include collaborating with Bigelow Analytical Services, another Bigelow Laboratory fee-for-service facility, to screen the algal collection for a strain that most efficiently produces the compound desired for a specific end product.  We are then using the Bigelow Seawater Suite to optimize growth conditions, generate a better understanding of the pilot scale financial model and mass-produce that strain.  When a desired culture is selected for a specific activity we will hold it in a private collection to ensure a clean back up is always available.  The private collection service offered by NCMA is a useful tool for companies developing a risk management plan.  As algal related products approach commercialization, the NCMA offers multiple options for licensing agreements (see below).  At this point in the commercialization process private collection cultures can transfer to patent deposits for the patent application process, as NCMA is also a WIPO Patent Deposit Authority. 

Licensing options

Exclusive License – strain(s) cannot be sold to or licensed by any other entity.  Royalty payment is the greater of $10,000/year flat fee or 1.5% royalty, up to a maximum of $100,000/year; provided that if NCMA (Licensor) receives a bona fide competing offer to license the strain on comparable terms at a royalty rate that is greater than the current royalty, NCMA will promptly and in good faith negotiate an adjustment to such royalty rate taking into consideration the competing offer(s) for exclusive licensing and further provided that in no event will the royalty exceed the greater of a royalty rate of 3% or $250,000/year.

Semi-Exclusive License – strain(s) cannot be sold to or licensed by any other commercial entity but can be sold to academic parties.  Royalty payment is the greater of $5,000/year flat fee or 0.5% royalty, up to a maximum of $35,000/year.

Non-Exclusive License – strain(s) can be sold to or licensed by any other entity.  Royalty payment is the greater of $2,500/year flat fee or 0.25% royalty, up to a maximum of $10,000/year.

Note: For Exclusive and semi-exclusive license agreements, the sale of licensed strain(s) will be restricted upon execution of the agreement.  A notification of change in commercialization status will be sent to customers who had purchased the same strain within a time period of 3 years prior to the license agreement.

Please wait...

Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×